th birthday.
the subject of an increasing number of studies, pointing essentially to its promising biological activities: thus, there is a surprising variety of beneficial properties to date attributed to resveratrol, summarised in a number of reviews [5, 6, 8, 9] and in a recent book [10] , and including antimicrobial activity, inhibition of prostaglandin biosynthesis, inhibition of platelet aggregation, anti-oestrogenic activity, neuroprotection, radio-protection, immunomodulation, and other biological activities. However, the most promising studies for possible biomedical application of resveratrol are probably those related to its cancer chemopreventive activity, originally evidenced in a widely cited article published in Science in 1997 [11] . Since then, many literature reports have shown that 1 is able to inhibit carcinogenesis and tumour cell cycle progression, as well as to interfere with intracellular signal transduction regulating cell survival and apoptosis (programmed cell death) in various human cancer cell lines [12, 13] . The large amount of data available now on resveratrol indicates that it may prove useful not only in cancer chemoprevention, but also in cancer chemotherapy. In fact, evidence has been gathered showing that resveratrol is active in vivo as an anti-tumor agent, while at the same time being quite safe in humans [5, 6] . In addition, studies highlighting its properties as an inhibitor of cell survival signal transduction, as an inhibitor of angiogenesis and as a sensitizer to stimuli inducing apoptosis [14] , suggest its possible use as an adjuvant in cancer chemotherapy, for instance in reducing resistance of tumour cells to the currently used anticancer drugs.
Nevertheless, the available in vivo studies indicate that 1, although absorbed to a great extent by the organism, has a poor bioavailability, and is largely metabolized to either glucuronide or sulphate [15] . In addition, it has been hypothesized that resveratrol is converted in vivo into compounds maintaining its anti-oxidative properties, but lacking its antiproliferative activity [9] . Thus, a possible clinical use of 1 requires a better understanding of its pharmacokinetic properties and a careful evaluation of its effective doses in vivo. In this scenario, the chemical modification of this natural 'lead compound' to obtain analogues with better bioavailability and/or enhanced activity is receiving increasing attention. In addition, comparative studies of the biological properties of resveratrol analogues are undoubtedly useful in view of a better understanding of structure-activity relationships (SAR), as well as of the mechanism of action of stilbene-based bioactive compounds.
On this basis, we report here a short summary of the state-of-the-art on resveratrol analogues as a starting point for future studies. Nevertheless, there is a plethora of natural products (and synthetic analogues) based on a stilbenoid structure [16] , many of them being either dimers or oligomers of the simplest stilbenoids or only remotely related to 1. Thus, in view of the limited scope of this review, we have focused our report on the most recent results on anti-tumor activity (and related properties) of compounds strictly related to the natural lead 1, namely those based on the transstilbene structure with the exact biogenetic skeleton C 6 -C 2 -C 6 . As a general outline, alkylated and hydrogenated stilbenoids, oligomers, phenanthrenes and other related analogues, as well as the oestrogenic drug diethylstilbestrol (DES) and derivatives were not included. With the exception of some compounds strictly related to Z-resveratrol (2) (an isomer of 1 found in red wine [17] and other natural sources [18, 19] ), cis-stilbenoids, and in particular the potent tubulin inhibitor combretastatin A4 (3) and its analogues are not reviewed here. In fact, excellent reviews on combretastatins and analogues have been recently published [20] [21] [22] .
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In order to facilitate the search for a specific stilbenoid, compounds included here are grouped according to their substitution pattern, namely the number of oxygenated functions (mainly hydroxyl or methoxyl groups) on the trans-stilbene nucleus; a separate section (miscellaneous compounds) was devoted to stilbenes with nitrogenated or halogenated constituents; some alkylated stilbenes were also included in this section. Apart from a few exceptions, only the most recent results (2004 -2006) have been reviewed, due to space limitations, as well as the recent publication of some interesting reviews on resveratrol analogues [23] [24] [25] [26] .
Mono-and dioxygenated analogues
Among the natural products strictly related to resveratrol, the 3,5-dihydroxystilbene, pinosylvin (4), found mainly in Pine wood, is known to possess antimicrobial and anti-insect properties [16, 27] , and was also reported as a potent antiproliferative agent in both oestrogen dependent breast cancer cell lines MCF-7 and T-47D [25] . This compound has recently been evaluated against HepG2 liver cancer cells and MDA-MB-231 (oestrogen non-dependent) breast cancer cells, displaying IC 50 values in the range 10-12 μg/mL [28] .
The higher antioxidant activity of ortho-and paradihydroxy stilbenes in comparison with other substitution patterns has been reported previously [29] . More recently, a possible relationship of the 3,4-dihydroxy structural moiety with the anti-tumor properties has been reported [24, 30] : in fact, the ortho-dihydroxystilbene 5, as well as the trihydroxystilbenes 38 and 39 (see next Section), resulted not only in more effective antioxidants (linoleic acid peroxidation) than 1, but also showed higher pro-apoptotic activity towards Jurkat cells and HL-60 leukaemia cells (EC 50 values in the range 20 -38 μM) with respect to 1 (EC 50 = 85 μM). Conversely, the analogues 4, 6, 7 and 8, lacking the catechol group, showed lower antioxidant and proapoptotic activity than that of 1.
In the frame of SAR studies of resveratrol analogues, a parallel solution-phase synthesis afforded a library of 30 E-stilbene analogues with a monohydroxylated ring, and including methoxylated and fluorinated substituents on the other ring (see miscellaneous compounds) [31] ; these products were evaluated against the HCT-116 (colon) and MDA-MB-468 (breast) cancer cell lines, the latter being more sensitive and showing growth inhibition by the synthetic stilbenes in the low micromolar range (1.4 < GI 50 < 25.7 μM). Against the MDA-MB-468 cell line, all the analogues proved more active than 1 (GI 50 = 41.1 μM); in particular, one of the most active compounds, 9 (GI 50 = 2.7 μM), was significantly more active than its isomer 10 (GI 50 = 25.7 μM).
It is known that the transcription nuclear factor kB (NF-kB), which regulates the expression of numerous genes promoting the prosurvival, antiapoptotic state, is up-regulated in many cancer cells. A very recent screening for the inhibition of the TNFα-induced activation of NF-kB has been carried out on 75 trans-stilbenes, with various substituents, including nitrogenated groups and halogens [32] .
In this screening, a number of resveratrol analogues were more active than 1, and the most promising compounds were subjected to a further evaluation of both antioxidant activity and inhibition of NF-kB activation. Among these compounds, the monoethoxystilbene 11 (IC 50 = 0.3 μM) and the dimethoxystilbene 12 (IC 50 = 0.6 μM) were significantly more effective inhibitors than resveratrol (IC 50 = 20 μM), although lacking any antioxidant activity: this was confirmed by the other assays (see the following Sections) showing that the most potent inhibitors of the activation of NF-kB generally did not exhibit antioxidant activity.
Trioxygenated analogues
The natural 3,5-dimethylated analogue of resveratrol, pterostilbene (13) , found in some berries and grape varieties, has previously been reported as antioxidant and cancer chemopreventive [25, 33] . In a more recent search for antiproliferative analogues of resveratrol with a longer half-life [34] , it was found that 13, when used in association with the flavonoid quercetin, caused a 56% (15), previously known as a natural product [37] , proved one of the most active compounds, with IC 50 values of 0.8 and 0.9 μg/mL towards A549 (lung) and Col2 (colon) cancer cells, respectively [38] . The Z-stereoisomer 16 was examined in a study focusing on human colon cancer Caco-2 cells, and exhibited a very potent anti-mitotic activity with 80% growth inhibition at 0.3 μM [39]: 16 was 100-fold more active than 15 and 1, and inhibited tubulin polymerization in a dose dependent manner (IC 50 = 4 μM), causing the cell cycle arrest at the G2-M phase transition. In addition, it reduced the depletion of polyamines and strongly inhibited the binding of radiolabeled colchicines to tubulin. These results prompted the authors to continue their studies on both 15 and 16.
Because the observed cytotoxicity of 16 was not related to a pro-apoptotic effect on Caco-2 cells, which express a mutated p53 gene, they investigated the pro-apoptotic effect of 16 on two human lymphoblastoid cell lines that differ in the status of their p53 gene: TK6 (expressing wild-type p53) and NH32 (p53-knockout cells) [40] . The results clearly demonstrated that 16 induces apoptosis regardless of the p53 status of the cells, although the mechanism remains to be clarified. The authors also suggested that the higher lipophylicity of 16 with respect to 1 may favour interaction with the cell membrane and consequently to its pro-apoptotic properties.
Recently, a small library of resveratrol analogues was prepared (see also the Sections below) [41] . All compounds were tested against the HL-60 leukaemia cell line both for cytotoxic (IC 50 ) and proapoptotic activity (AC 50 In a comparative study on the antiproliferative properties of 1 and seven analogues (including naphthalene-based compounds) [43] , the three methylated analogues 13, 15, and 21 were tested against breast cancer cells MDA-MB-231: among these compounds, 15 was the most potent (IC 50 = 1.2 μM), followed by 13 (IC 50 = 10.0 μM). Interestingly, 21 (IC 50 > 50 μM) proved less active than 1 (IC 50 = 20.5 μM), and the authors argue that this is further evidence in favour of the previously reported essential role of the 4'-hydroxy group for the antiproliferative activity of resveratrol [44] . In this connection, we have recently evaluated the H-donating ability of the three hydroxyl groups in resveratrol through a laser flash-photolysis study. We found that the 4'-hydroxy appears to be the most reactive due to the high stability of the corresponding phenoxyl radical by conjugation with the rings [45] .
In a recently published cytotoxicity evaluation, a series of 17 resveratrol derivatives, including brominated stilbenoids (see miscellaneous compounds), were tested against the KB (human oral epidermoid carcinoma) tumour cell line [46] ; compound 15 (IC 50 = 7.40 μM), although proving more active than the anticancer drug 5-fluorouracil (IC 50 = 13.4) and one of the most active compounds, was less active than the brominated analogue (84). Recently, 15 has been shown to exert potent antiangiogenic activity [47] , a property which appears to be highly promising in the search for new anticancer therapeutic agents because of the important role of neovascularisation in neoplasia [48] . In this study, 15 was evaluated for its capacity to affect different steps of the angiogenesis process in comparison with 1 and other analogues, including dihydroresveratrol and the partially methylated analogues 13 and 21. Interestingly, hydrogenation of the central double bond in 1 or methylation only at the 4' position suppressed the antiangiogenic activity of resveratrol. The activity was significantly potentiated by methylation at the 3,5 positions and further methylation at 4' caused a 30 to 100 fold higher activity than 1. It should also be mentioned that in a recent study on the inhibitory activity towards cytochromes P450 1A2 and 2E1 [49] , compounds 13, 15 and other monomethylated analogues showed comparable inhibitory activity towards CYP1A2, and were more active than 1: this suggests that neither the number nor the position of methoxy groups are critical for the inhibition of CYP1A2, but their presence increases the inhibitory activity.
Employing standard chemical conversions and a chemo-enzymatic methodology for regioselective acylation of resveratrol, we have carried out the preparation of a small library of lipophilic analogues [50, 51] . By regioselective acetylation catalysed by Candida antarctica lipase (CAL) in organic solvent, 1 afforded 4'-acetylresveratrol (22) . CAL biocatalysed regioselective alcoholysis of 3,5,4'-triacetylresveratrol (23), 3,5,4'-tributanoylresveratrol (24) and 3,5,4'-trioctanoylresveratrol (25) gave the selectively acylated analogues 26 − 31 in good yields. Further resveratrol analogues were obtained through methylation (15 and 32) and hydrogenation reactions (these products are not reported here), whereas the 3,4,4'-trimethoxystilbene (33) was obtained by complete synthesis. These 18 compounds were evaluated as antiproliferative agents on androgen non-responsive human prostate tumour cells DU-145: most of the compounds showed either higher or comparable activity to that of 1 (GI 50 = 24.09 μM), the most potent being 15 (GI 50 = 2.92 μM), followed by the partially methylated analogue 32 (GI 50 = 12.24 μM). Some acylated analogues (23, 24, 28, 29) were slightly more active than 1; hydrogenation caused only small variations in the activity, and this result seems in contrast with data recently reported by others [52] . More recently, we tested resveratrol, its analogues 15, 32 and 33 and their Z-isomers 2, 16, 34 and 35 on a set of four human cancer cell lines: M-14 (human melanoma), LNCaP (androgen responsive human prostate tumour), DU-145 and KB [53] . The methylated analogues of 1 were more active than the natural lead compound in the large majority of bioassays. The most active compound was 16, exhibiting antiproliferative activity comparable to that of the anticancer drug vinorelbine against DU-145 and LNCaP cells, and gave a GI 50 value of 0.1 μM against KB cells. Some methylated Z-isomers displayed a higher activity than their relevant E-isomers, but a general rule stating that stilbenoids with a Z configuration of the double bond display a considerably higher antiproliferative activity than their E-isomers could not be established. In particular, 1 was more active than 2 towards all the tested cell lines. 
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The use of levulinate and chloroacetate protecting groups under palladium-N-heterocyclic carbene (NHC) catalyzed decarbonylative coupling conditions allowed the synthesis of the selectively mono-and diacetylated analogues 22, 26, 36, 37 [54] . These acetates, as well as a series of fluorinated resveratrol analogues (not reported here), were tested against HL-60 leukaemia cells: only compound 22 (IC 50 = 17 μM) proved more active than 1. However, the authors report that all the fluorinated analogues were toxic to the HL-60 and other cells, limiting their potential for future investigations.
As cited above, a parallel solution-phase synthesis was used to obtain a library of E-stilbenoids, evaluated as antiproliferative agents. Of these, compound 19 was the most potent against breast cancer cells MDA-MB-468 (GI 50 = 0.96 μM) [31] .
Its growth-inhibitory activity was approximately twice that of its 2'-and 4'-isomers. The activity of the most potent antiproliferative agents towards breast cancer cells was correlated to their ability to induce apoptosis. The authors suggested that the potency of the reported resveratrol analogues does not primarily reside in their growth-inhibitory activity, but rather in their selective pro-apoptotic properties.
The trihydroxystilbenes 38 and 39 were included in the above cited comparative study [30] on antioxidant and pro-apoptotic activity of 1 and other mono, di-and tryhydroxylated stilbenes. Both exhibited higher activities than 1, confirming the importance of the ortho-dihydroxy moiety. In a more recent study, 39 rapidly induced apoptosis in Jurkat cells, unlike 1 [55] . It induced activation of caspase-8 and apoptosis by a Fas-associated death domain (FADD), protein-dependent mechanism that was unresponsive to resveratrol.
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The above cited, very recent screening of 75 resveratrol analogues as antioxidants and inhibitors of the TNFα-induced activation of NF-kB [32] included some trioxygenated stilbenes that were more effective inhibitors than 1. Among them, the stilbenes 40 and 41 were potent inhibitors, with IC 50 values of 0.5 and 0.6 μM, respectively. As reported above, compounds incorporating an orthodihydroxy group were also good antioxidants, although inhibition of NF-kB is not necessarily related to the presence of either free hydroxyl groups or antioxidant activity.
Tetraoxygenated analogues
Piceatannol (42), known also as astringinin, is a naturally occurring analogue of resveratrol, bearing an additional OH group at C-3'. It has been found in sugar cane, berries, peanuts, grapes and other plants [6, 25] . Piceatannol has a variety of biological properties, among them antioxidant and anti-tumor [25] . As reported in a recent review [26] , the Piceatannol and resveratrol were recognized as potential inhibitors of CNS-associated kinases through an in silico screening method: in in vitro kinase assays, 42 proved to be a potent inhibitor of CNS associated kinases CK2 and PKD and the purified CNS complex [61] . In a further recent work, both 1 and 42 were demonstrated to be less potent antiproliferative and apoptosis-inducer agents than their 3,5-methylated analogues, respectively 13 and 44 [35] . In particular, 44 was 50-97 times more potent than 1 in inducing apoptosis, not only in sensitive HL-60 leukaemia and human T-lymphoma (HUT-78) cell lines, but also in resistant lymphoma and leukaemia cell lines. Interestingly, 44 has a noticeable pro-poptotic activity against the MDR leukaemia cells, with an AC 50 value of 5 μM (HL-60R) and 3.5 μM (K562-ADR).
In a SAR study of six polyhydroxystilbenes evaluated for their pro/antioxidant and cytotoxic activity [62] , compounds 42, 45 and 46 showed cytotoxic activity towards HL-60 (leukaemia) cells comparable to that of 1, although they were less active than the hexahydroxystilbene 71 (see hexaoxygenated analogues). The most potent radical scavenger was 42, but also the stilbenes 45 and 71, bearing an ortho-dihydroxy group, were thousands-fold more effective than 1 and 46. Orthohydroxystilbenes showed more than three-fold higher cytostatic activity than those compounds with a different substitution pattern, and their oxidation in a microsomal model system resulted in the formation of ortho-semiquinones; these intermediates undergo redox-cycling, thereby forming cytotoxic oxygen radicals. Thus, the authors suggest that the increased cytotoxicity of ortho-hydroxystilbenes is related to the presence of ortho-semiquinones formed during either metabolism or autoxidation. In a more recent work, 42 showed a protective effect against the DNA oxidative damage in leukaemic cells higher than that of 1 [63] .
Rhapontigenin (47), a stilbene abundant in Rheum undulatum [64] , is the 4'-O-methylated analogue of 42 and the main active metabolite of the glycoside rhaponticin. It was previously reported as a potent and highly selective inhibitor of human cytochrome P450 1A1 and 1B1 [25] , and has recently been tested on HepG2 liver cancer cells and proved moderately active (IC 50 = 115 μg/mL) [65] . In the above cited biological evaluation of a series of E-and Z-stilbenes [36] , 47 (IC 50 = 48 μM; AC 50 > 200) was less cytotoxic and less of an apoptosis-inducer than 1 on HL-60 leukaemia cells; its analogue, 48, was only slightly more active, whereas the analogues 49 and 50 were highly active (IC 50 and AC 50 < 1 μM). Their Z-stereoisomers 51 (IC 50 = 0.03 μM; AC 50 = 0.04 μM) and 52 (IC 50 = 0.05 μM; AC 50 = 0.1 μM) were even more active, showing IC 50 and AC 50 values in the nanomolar range; in addition, these compounds were active toward MDR HL-60R cells and their activity was higher than that of known anticancer drugs. In the same evaluation, the 3'-amino analogue of 51 (76, see miscellanous compounds) showed the same activity. The authors suggested that the main mechanism of cytotoxicity of 51 and 76 could be activation of apoptosis.
Another natural analogue of 1, oxyresveratrol (53), is a major component of the heart-wood of Artocarpus lakoocha [66] and was also found in other plants [6] . It showed a lower cytotoxic activity (IC 50 > 20 μg/mL) than 1 on both lung (A549) and colon (Col2) cancer cells. The related 3,5,2',4'-tetramethoxy derivative, 54, was highly active, with IC 50 values of 0.8 (A549) and 0.8 (Col2) μg/mL, whereas permethylrhapontigenin (55) and 56, the latter with a different substitution pattern, were scarcely active, displaying IC 50 values greater than 15 μg/mL [38] . Oxyresveratrol is also known as a potent inhibitor of tyrosinase [67] , a key enzyme in biosynthesis of melanin pigments, and has potential as a skin depigmentation agent. Recently, some chemical conversions were carried out on 53 to evaluate the effect of these transformations on both the cytotoxic activity against the human cancer cell lines KB, BC (lung) and NCI-H187 (lung) and tyrosinase inhibition [52] : 53 proved to be noncytotoxic. Interestingly, when 53 was hydrogenated, a more potent tyrosinase inhibitor, devoid of any cytotoxicity, was obtained. Complete or partial methylation of 53 afforded the methoxy analogues 54 and 57 − 59; by photoisomerisation, 54 gave the Z-isomer 60. Among these stilbenes, 57 was either scarcely active or inactive; 54, 58 and 59 were moderately active (IC 50 in the range 5.5 -33.5 μM), whereas 60 was highly active, (IC 50 = 0.3 μM on KB and NCI-H187; 1.0 μM on BC) showing a cytotoxicity higher than ellipticine. When hydrogenated, 54 was completely inactive and, thus, the authors concluded that the central double bond and the presence of methoxy groups in stilbene analogues are both required for cytotoxicity.
In a study of pharmacokinetics in mice and anti-tumor properties on human colon cancer cells (HCA-7 and HT-29), the 3,4,5,4'-tetramethoxystilbene (61) was slightly more potent than 1 (IC 50 in the range 6 -26 μM) [68] . Interestingly, 61 showed a higher bioavailability compared to 1 in the small intestine and colon; in contrast to resveratrol, which is metabolized to either its sulphate or glucuronate conjugate, 61 underwent hepatic metabolic hydroxylation or single and double O-demethylation. The authors report also that, on the basis of unpublished results, 61 is devoid of any toxicity in rats when administered at single doses of up to 40 mg kg -1 (intravenous) or up to 400 mg kg -1 (oral). In this connection, it is worth mentioning here that 61 is currently under preclinical evaluation as a potential anti-tumor prodrug that undergoes metabolic activation by cytochrome P450 enzymes [69] . More recently, the same research group tested 61 as an inhibitor of adenomatous polyposis development in Apc Min+ mice, and found a 24% adenoma reduction produced by 61, whereas 1 decreased development by 27% [70] . In this study, 61, unlike 1, proved to be ineffective in decreasing COX-2 expression, although reducing prostaglandin E2 (PGE-2) production; this latter event was probably mediated by metabolites of 61. Another recent study has been carried out on 61 in comparison with 1, employing both normal and cancer cell lines [71] ; 61 was more potent than 1 against various cancer cell lines (WI38VA, IMR-90SV, HeLa, LNCaP, HT-29, and HepG2), but had almost no inhibitory effect on the growth of normal cells (WI38, IMR-90, BJ-T).
When the two compounds were tested on normal human fibroblasts (WI38), both had little inhibitory effect up to 50-100 μM; on transformed fibroblasts (WI38VA), 61 completely inhibited the growth at 1-2 μM, whereas 1 was effective only at concentrations higher than 50 μM. Further analysis revealed that 61 causes a selective activation of the mitochondrial apoptotic pathway in WI38VA, but not in WI38 cells, and the authors suggest that this could be a major reason for the striking differential growth inhibitory effect of 61.
In the above cited SAR study of 3,5-dimethoxy analogues tested on sensitive leukemia cells (HL-60) and MDR leukaemia cells (HL-60R and K562) [42] , the tetraoxygenated stilbenes 62 and 63 were examined, the latter being significantly active against HL-60 cells (IC 50 = 3.5 μM).
Pentaoxygenated analogues
In the above reported SAR study of polyhydroxystilbenes, the pentahydroxystilbene 64 was slightly more cytotoxic than 1 on HL-60 cells, and was clearly more effective as an antioxidant [62] . The above cited cytotoxicity evaluation of resveratrol analogues towards A549 (lung) and Col2 (colon) cancer cells [38] included four pentamethoxy derivatives, namely 65 and the stilbenes 66, 67 and 68, examined as E/Z mixtures.
All these samples showed cytotoxic activity either comparable to or lower than that of 1. Compound 65 and its Z-isomer 69 were recently tested against HL-60 leukemia cells in comparison with 1 and other methoxylated stilbenes [41] . The cytotoxic and pro-apoptotic activities of 69 (IC 50 = 1.8 μM; AC 50 = 2.6 μM) were approximately ten-fold higher than those of 65 (IC 50 = 22 μM, AC 50 = 42 μM). Compound 70, the 4-demethylated analogue of 65, was recently tested on sensitive and MDR leukaemia cells [42] , but was scarcely active. 
Hexaoxygenated analogues
As discussed above, the hexahydroxystilbene 71 showed the highest cytotoxic activity (IC 50 = 4.2 μM) towards HL-60 cells when compared with 1 and other stilbenes bearing four (42, 45, 46) or five (64) hydroxy groups. Stilbenes with a pyrogallol and/or catechol groups, including 71, exhibited an antiradical activity far higher than 1, as confirmed by a further study [63] in which 71 exhibited a more potent protective effect against H 2 O 2 -induced DNA damage in leukaemia cells than either 1 or 42. Due to its promising biological properties, 71 was studied in-depth in a more recent work focusing on its cytotoxic and biochemical effects on HL-60 leukaemia cells [72] . This compound induced apoptosis at concentrations significantly lower than 1 and the authors suggest that it could notably inhibit the activation of the nuclear transcription factor NF-kB; it arrested cells in the S phase of the cell cycle while depleting cells in the G2-M phase.
In growth-inhibition experiments, 71 gave an IC 50 value of 6.25 μM, whereas the value for 1 was 12 
Miscellaneous stilbene-based compounds
In addition to the resveratrol analogues reported above, some stilbenes substituted with either nitrogen or halogen groups have recently been obtained, some of them possessing noticeable antitumor properties, and thus are worthwhile reporting here. A few methylated stilbenes have also been included in this section.
The above-cited series [36] of E-and Z-stilbenes include some amino-analogues of resveratrol and rhapontigenin [36] . Again, these Z-isomers were more active than the related E-isomers as antiproliferative and apoptosis-inducing agents towards HL-60 leukaemia cells. 
Conclusions
The recent literature on stilbene-based resveratrol analogues has been reviewed, and a total of 94 compounds are reported (see structures 4 -97), selected either for their promising anti-tumor properties or for comparative purposes in SAR studies. As a general outline, these recent literature data confirm the previously reported observation that minimal modification in the nature and position of the substituents on the stilbene nucleus may cause large variations in biological activity and, more specifically, in the compounds anti-tumor properties. Among the polyhydroxylated stilbenes, it has been firmly established that those with either a catechol or pyrogallol moiety are by far better radical scavengers than 1 or other analogues lacking an ortho-dihydroxy group; this property was also shown to be related to pro-apoptotic activity. Some authors suggest that the increased cytotoxicity of ortho-hydroxystilbenes is related to the presence of ortho-semiquinones formed during either metabolism or autoxidation. The essential role of the 4'-hydroxy group for the antiproliferative activity of resveratrol has been claimed by some authors, but there are a number of stilbenes that exhibit potent antiproliferative activity in which the 4'-hydroxy group is either substituted or absent; important examples are compounds 11, 12, 15, 19 and 54. A plausible hypothesis is that the anti-tumor properties of stilbenoids with free hydroxy groups reside in a different mechanism of action with respect to those where the hydroxy groups are blocked, as in polymethoxystilbenes.
The importance of the central double bond has been confirmed: with few exceptions, dihydrostilbenes are either less active than the unsaturated related compounds, or devoid of any activity. This is in agreement with observations made on hydrogenated combretastatin analogues, suggesting an entropic penalty associated with conformationally free derivatives [22] .
In the large majority of cases where pairs of E-and Z-isomers were evaluated for either cytotoxic or pro-apoptotic activity, the Z-isomers proved significantly more active than their E analogues; a striking difference was observed for the E/Z couples 15/16, 54/60, 49/51, 50/52 and 65/69, all bearing two or three methoxylated groups in ring A, but also for the amino-analogues 77/76 and the bromoanalogues 82/83. Previous reports document well that Z-stilbenes are more potent microtubule interactors than their E-isomers [74] ; nevertheless, the antiproliferative/apoptotic activity ratio between the E/Z isomers reported here has wide variations and in some cases both either have comparable activities or the E-isomer may be even more active, as for E and Z-resveratrol. Thus, a general rule stating that stilbenoids with a Z configuration of the double bond display a considerably higher antiproliferative activity than their E-isomers cannot be considered as established. The structural analogy of methoxylated Z-stilbenoids with combretastatin A4 (3), as well as the similarities of biological properties observed in some cases, like the inhibition of tubulin polymerisation, prompts the hypothesis that, at least in part, these two families of related stilbenoids may share a similar mechanism of action, for instance, a preferential interaction with a receptor. Nevertheless, the observation that Z-resveratrol has a low activity has been highlighted by some authors, who argued that the interpretation of the available data is not straightforward.
A variety of methoxystilbenes (and one ethoxystilbene) has recently been reported: these analogues showed, in many cases, either potent antiproliferative, pro-apoptotic activity or strong inhibition of TNFα-induced activation of NF-kB. (see for instance 11, 12, 15, 19, 49, 54 and related Z-isomers). Substitution with larger groups generally afforded analogues with either lower or comparable activity, but it is worthy of mention that the brominated derivative 84 was more active than 5-fluorouracil towards KB cells. In the most potent analogues, close to the nanomolar range of activity, a 3,5-dimethoxy or a 3,4,5-trimethoxy moiety (ring A) is generally present, but minimal structural differences cause significant difference in activity. For instance, it is interesting to compare 13 with either 15 or 19, the latter with 17, and 48 with 49. In contrast, it is rather surprising that 51 and 76 exhibit an identical activity. Globally considered, polymethoxystilbenes appear as a sub-group of great interest among the resveratrol analogues; these analogues are worthy of a deeper evaluation also in relation to their potential anti-angiogenic properties. In addition, in vivo studies indicate that methoxystilbenes undergo different metabolic conversion and have a higher bioavailability with respect to resveratrol.
The potent activity of some amino-and halogenated stilbenes, and in particular 76, 91 and 92 is undoubtedly worthy of attention, but the toxicity of these compounds to normal cells has rarely been evaluated and some of them have been indicated as being too toxic to justify future investigations.
In conclusion, the synthesis and evaluation of stilbene-based resveratrol analogues has proved to be a highly active field of research and has recently afforded compounds with cytotoxic and proapoptotic activity in the nanomolar range. Nevertheless, the exact structural determinants to optimize the anti-tumor properties of these compounds and details of their mechanism of action remain to be clarified. Future studies on either previously reported or new analogues will certainly be useful for a better understanding of the biological activity of the stilbenoid class, and hopefully may afford either new anti-tumor compounds or adjuvants of the anticancer drugs in current clinical use.
